Sanofi agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as the French pharmaceuticals firm bets on next-generation mRNA vaccine technology beyond the Covid-19 pandemic, confirming a Reuters exclusive report.

Bristol Myers Squibb Co. was sued for $6.4 billion on June 3 for allegedly delaying the company’s Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought in 2019.

Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital. 

Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. 

AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.

AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.

ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.

Shares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.

Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.

The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.